Andy Vicari & Dr. Anne Peters: May 15, 2020

Lilly and Beyond Type 1 share medical and insulin affordability considerations for the diabetes community amid COVID-19



Andy Vicari

Senior Director & U.S. Brand Leader, Insulins, Eli Lilly and Company

Anne Peters, MD

Beyond Type 1 Science Advisory Committee

Contracting and treating COVID-19 can be worrisome for people with diabetes, as these individuals are more likely to experience complications. With this in mind, Eli Lilly and Company and Beyond Type 1, a diabetes advocacy group, are working to ensure that people living with diabetes are prepared to manage their condition throughout the COVID-19 pandemic. Lilly recently introduced the new Lilly Insulin Value Program, allowing anyone with commercial insurance, or who is uninsured, to fill their monthly prescription of Lilly insulin for $35. Beyond Type 1 is also addressing the medical considerations of people with diabetes, providing the community the information they need to proactively care for their health amid the COVID-19 crisis. 


Did you know: 

  • Beyond Type 1 provides tips for people living with diabetes to proactively care for their health during the COVID-19 crisis. They can ward off respiratory system threats by practicing simple habits including: frequently washing hands, staying home except when absolutely necessary and maintaining six feet of distance between themselves and others when outside the home.
  • On April 7, Lilly introduced the Lilly Insulin Value Program, allowing anyone using commercial insurance, as well as the uninsured, to fill a monthly prescription of Lilly insulin for $35 with a co-pay card.
  • Anyone who has lost employment and uses Lilly insulin should call the Lilly Diabetes Solution Center at 833-808-1234, Monday-Friday 8 a.m. to 8 p.m. ET to learn about the affordability options. For people with an urgent need for insulin and nowhere else to turn, the Lilly Diabetes Solution Center can provide immediate help.


On May 6, 2020, Andy Vicari and Dr. Anne Peters are available to you and your listeners to talk about COVID-19 as it relates to the diabetes community as well as affordable resources for people who use Lilly insulin.

For more information please visit 



Andy Vicari is Senior Director & U.S. Brand Leader for the Insulins portfolio at Eli Lilly and Company. In this role, Andy leads the brand teams in developing and executing cross-portfolio marketing strategies across various insulin brands at Lilly. Andy has held several leadership positions in sales and marketing. Outside of work, Andy serves on the Board of Directors for the American Diabetes Association. He earned a bachelor’s degree in Biomedical Sciences from St. Cloud State University and a Master of Business Administration from the University of Illinois at Urbana-Champaign.



Anne L. Peters, MD, is a professor of clinical medicine at the Keck School of Medicine of the University of Southern California and the Director of the USC Clinical Diabetes Programs. She runs diabetes centers in Beverly Hills and in underserved East Los Angeles. In addition to her clinical work, she has been a PI on multiple grants and has written over 200 abstracts and articles and 4 books. Her major interests involve translating research findings, from lifestyle interventions to technology, to people with diabetes throughout the socioeconomic spectrum. She has been part of the writing groups for the ADA guidelines for the treatment of both type 1 and type 2 diabetes, is a member of the EASD/ADA Device Safety committee, Chair of the Endocrine Society Technology Guideline Writing Group, the JDRF Technology Education Initiative and the ADA Technology Interest Group. She is also a member of the ADA Professional Practice Committee. She was presented with the ADA “Outstanding Physician Clinician” award, the Bernardo Alberto Houssay Award from the National Minority Quality Forum and has been listed on the “Best Doctors in America” continuously since 2001



Speak Your Mind